rss
Br J Ophthalmol 2004;88:892-895 doi:10.1136/bjo.2003.036285
  • Clinical science
    • Scientific reports

Post-brachytherapy initial tumour regression rate correlates with metastatic spread in posterior uveal melanoma

  1. I Kaiserman,
  2. I Anteby,
  3. I Chowers,
  4. E Z Blumenthal,
  5. I Kliers,
  6. J Pe’er
  1. Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel
  1. Correspondence to: Dr I Kaiserman Department of Ophthalmology, Hadassah University Hospital, POB 12000, IL-91120 Jerusalem, Israel; Igorkcc.huji.ac.il
  • Accepted 11 December 2003

Abstract

Aim: To confirm the prognostic value of post-brachytherapy initial tumour regression rate in posterior uveal melanoma.

Methods: A prospective, comparative, observational cohort study was carried out on 147 eyes (147 patients) with choroidal melanoma (mean age 61 years) treated with Ru-106 brachytherapy. Observation procedure: Patients were followed clinically and ultrasonically every 6.7 (SD 0.3) months (1001 examinations). On average each patient was examined 5.8 times (mean follow up 9.6 (3.7) years). The echographic parameters included tumour base size, height, internal reflectivity, regularity, vascularity, and extrascleral extension. The clinical follow up included ocular examination and periodic metastatic screening (liver function tests and liver imaging). Main outcome measures were risk of liver metastasis in correlation with the post-brachytherapy initial tumour regression rate.

Results: At brachytherapy the mean tumour height was 5.2 mm (range 2.2–11.8 mm). After brachytherapy 142 tumours (96.6%) responded by a decrease in height. The initial height regression rate was 6.1% (0.8%) per month in patients who later developed metastasis v 4.3% (0.4%) per month in those who did not. Tumours higher than 6 mm, tumours with an internal reflectivity smaller than 50%, and tumours with an initial rate of height regression larger than 0.7 mm/month (10% per month) had higher 5 year melanoma related mortality. Kaplan-Meier survival analysis and the multivariate Cox proportional hazards model showed a significant role for tumour height and initial tumour regression rate on patients’ survival.

Conclusion: This study confirms that post-brachytherapy initial tumour regression rate has a prognostic value.

Footnotes

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.